Carisma Therapeutics (NASDAQ:CARM) Rating Reiterated by HC W

Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 121.33% from the stock’s previous close. Other analysts have also […]

Related Keywords

California , United States , , Barclays Plc , Jefferies Financial Group , Wells Fargo Company , Citigroup Inc , Carisma Therapeutics Inc , Manufacturers Life Insurance Company , Carisma Therapeutics , Get Free Report , Financial Group , Therapeutics Stock Down , State Teachers Retirement System , Carisma Therapeutics Daily , Nasdaq Carm , Carm , Medical , Reiterated Rating , Hc Wainwright ,